Here are a few analogies to describe Plus Therapeutics (CNSY):

• The Moderna or BioNTech for central nervous system cancer radiotherapy.
• A specialized Novartis or Pfizer oncology unit, focused on pioneering radiation treatments for brain tumors.

For the public company Cerenome (symbol: CNSY), based on the provided company description (which details Plus Therapeutics, Inc., a clinical-stage pharmaceutical company), the company does not currently have major customers.

As a clinical-stage entity, its primary activities are focused on research, development, and conducting clinical trials for its drug candidates (e.g., Rhenium-186 NanoLiposome). Products are not yet commercialized or approved for sale, meaning there are no direct purchasers of its therapies at this time.

• Pfeiffer Vacuum Technology AG (PFE.DE)
• Solvay S.A. (SOLB.BR)
• C-Squared Bio
• Almac Pharma Services
• Takeda Pharmaceutical Company Limited (TAK)

Marc H. Hedrick, M.D. President and Chief Executive Officer

Dr. Marc Hedrick has been the President, Chief Executive Officer, and Director of Plus Therapeutics, Inc. since 2014. He previously co-founded and served as President and Chief Executive Officer of StemSource Inc.. Dr. Hedrick also held executive leadership roles, including President, CEO, and Director at Cytori Therapeutics, Inc., the company's former name. He is a trained general, vascular, and plastic surgeon, and a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA).

Andrew J. Sims, CPA Vice President and Chief Financial Officer

Mr. Andrew J. Sims has served as the Chief Financial Officer and Vice President of Plus Therapeutics, Inc. since 2020. He previously held Chief Financial Officer roles at several private equity-backed companies. His experience includes a focus on mergers and acquisitions, corporate capitalization, and building and managing teams to support global growth. Prior to joining Plus Therapeutics, he was a Partner at Mazars, a global accounting, advisory, audit, tax, and consulting firm, where he led over 50 acquisitions.

Eric J. Daniels, M.D., MBA Chief Development Officer

Mr. Eric J. Daniels was appointed Chief Development Officer of Plus Therapeutics, Inc. in April 2026. He has over two decades of experience in clinical development, regulatory strategy, corporate operations, and business development. Previously, he served as Chief Development Officer at Kiora Pharmaceuticals and held senior leadership roles at Cytori Therapeutics, Inc., as well as serving as CEO of OccuRx.

Russ Havranek, MS, MBA EVP, Commercial and Corporate Strategy

Mr. Russ Havranek is the Executive Vice President of Commercial and Corporate Strategy at Plus Therapeutics, Inc.. He brings over 28 years of leadership experience in developing and commercializing diagnostic and therapeutic products for global, publicly traded biopharma and medical device companies. His background includes roles in marketing, strategy, business development, general management, and R&D at companies such as Johnson & Johnson, Guidant, Genentech, DJO Global, Volcano, and CareFusion. He previously served as Vice President of Global Marketing and Business Development at Cytori Therapeutics.

Richard J. Hawkins Chairman Executive Board

Mr. Richard J. Hawkins has been the Chairman of Plus Therapeutics, Inc. since 2018. His prior experience includes serving as the Chief Executive Officer of Lumos Pharma Inc. and as the Chairman, President, and Chief Executive Officer of Pharmaco.

The key risks to Cerenome's business (formerly Plus Therapeutics, Inc.) are primarily related to its financial viability as a clinical-stage pharmaceutical company, the inherent uncertainties of drug development and regulatory approval, and the competitive landscape of the biotechnology industry.

1. Going Concern and Need for Additional Capital: Cerenome faces substantial doubt about its ability to continue as a going concern due to ongoing operating losses and negative cash flows. The company is highly dependent on its ability to raise additional capital to fund its clinical development programs and commercialization efforts. As of March 2025, the company had an estimated cash runway of approximately nine months, with analysts forecasting several years until free cash flow break-even, indicating a persistent need for further financing.
2. Clinical Trial and Regulatory Approval Risks: As a clinical-stage pharmaceutical company, Cerenome's success hinges on the favorable outcomes of its clinical trials for lead drug candidates like REYOBIQ™ (rhenium obisbemeda) and subsequent regulatory approvals. There are no guarantees that its pipeline products will receive the necessary regulatory clearances or prove to be commercially successful. Recent feedback from the FDA regarding REYOBIQ™'s pivotal trial strategy for leptomeningeal metastases highlighted that while accelerated approval might be possible, the data were insufficient to support circulating tumor cells as an intermediate clinical endpoint, recommending an established clinical benefit endpoint such as overall survival. This could potentially impact clinical development timelines and increase the burden of proof for approval.
3. Competition and Intellectual Property Risks: Cerenome operates in the highly competitive biotechnology and pharmaceutical industries. It faces risks from competitors developing new products, achieving technological advances, and obtaining patents. The company's reliance on the effectiveness of its patents and other intellectual property protections for its innovative products, such as REYOBIQ™, also presents a risk, including the potential for patent litigation.

Cerenome, Inc. (NASDAQ: CNSY), formerly known as Plus Therapeutics, Inc., develops and commercializes treatments for patients with cancer and other diseases. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy targeting central nervous system (CNS) cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. Cerenome also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere for various solid organ cancers, such as primary and secondary liver cancers.

Currently, the addressable market sizes for Cerenome's main products are as follows:

• For recurrent glioblastoma, the global market size is estimated to be approximately $500 million.

Further specific addressable market sizes for leptomeningeal metastases, pediatric brain cancers, and various solid organ cancers, including primary and secondary liver cancers, were not readily available in the search results. Therefore, the market sizes for these products cannot be provided at this time.

Expected Revenue Growth Drivers for Cerenome (CNSY)

Cerenome (NASDAQ: CNSY), formerly known as Plus Therapeutics, Inc., is strategically positioned for future revenue growth over the next 2-3 years through a multi-faceted approach to central nervous system (CNS) oncology. Key drivers are expected to include the expansion of its diagnostic platform, the advancement of its lead therapeutic candidate, and synergistic partnerships.

• Expansion and Adoption of CNSide® Diagnostics Platform: Cerenome's commercially available and reimbursed CNSide® Diagnostic platform is a significant revenue driver. This cerebrospinal fluid (CSF)-based platform aids in the detection, molecular characterization, and longitudinal monitoring of CNS cancers. The company has recently expanded its commercial payer coverage for CNSide to approximately 126 million covered lives through new agreements with major insurers like Highmark, Blue Shield of California, and Elevance Health. Furthermore, Cerenome has seen a notable increase in test volumes, with 232 CNSide tumor cell enumeration tests performed year-to-date, and 18 institutions currently ordering the service. Continued growth in payer coverage and institutional adoption are expected to drive revenue in the diagnostic segment.
• Advancement and Potential Commercialization of REYOBIQ™ (rhenium Re186 obisbemeda): The company's lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is a patented radiotherapy currently in clinical trials for challenging CNS cancers, including leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. Positive clinical trial outcomes and subsequent regulatory approvals would pave the way for commercialization, representing a substantial new revenue stream.
• Strategic Integration of Precision Diagnostics, Targeted Therapeutics, and Artificial Intelligence: Cerenome's rebrand signifies its evolution into an integrated CNS oncology company, leveraging a multimodal strategy that combines precision diagnostics, targeted therapeutics, and artificial intelligence (AI). The company has a native artificial intelligence partnership, which is expected to yield improved outcomes in how CNS cancers are detected, treated, and understood. This integrated platform and AI capabilities could lead to the development of innovative solutions and enhanced service offerings, attracting new customers and partners.
• Enhancement of CNSide Capabilities Through Strategic Partnerships: Cerenome has partnered with Genomic Testing Cooperative to integrate its next-generation sequencing technology into the CNSide cerebrospinal fluid assay platform. This collaboration is expected to enhance the diagnostic capabilities of CNSide, making it a more comprehensive and appealing solution for clinicians and researchers. Such advancements can lead to increased demand and utilization of the CNSide platform, contributing to revenue growth.